AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00354874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salmeterol 50mcg
Description: salmeterol
Study NCT01872169 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Disordered eating screening questionnaire
Study NCT00848679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural lidocaine
Description: Epidural 2% lidocaine, administered in 5mL incremental boluses. Looking at dose-response effect.
Study NCT00848679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epidural lidocaine
Description: Epidural 2% lidocaine, administered in 5mL incremental boluses. Looking at dose-response effect.
Study NCT00848679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural lidocaine 2%
Description: 5 x 5ml boluses of either epidural lidocaine 2% or epidural saline
Study NCT00848679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epidural lidocaine 2%
Description: 5 x 5ml boluses of either epidural lidocaine 2% or epidural saline
Study NCT00821418 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PulseHaler treatment
Description: treatment is for two weeks, 3 times per day
Study NCT00821418 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CPAP treatment (through a deactivated version of PulsHaler)
Description: treatment is for two weeks, 3 times per day
Study NCT01352598 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: stereotactic body radiotherapy
Description: Patients will receive 30 - 40 Gy in 4 - 5 fractions. For high risk patients who also receive external beam radiotherapy, the SBRT will be given as 19 - 21 Gy in 2 - 3 fractions.
Study NCT04414982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Values Affirmation
Description: Participants are asked to circle the two or three values that are MOST important to them. Next, participants are asked to think about times when the values chosen might be important to THEMSELVES and then write a few sentences to describe when and why they might be important.
Study NCT04414982 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Values Affirmation
Description: Participants are asked to circle the two or three items that are LEAST important to them. Next, participants are asked to think about times when the values chosen might be important to SOMEONE ELSE and then write a few sentences to describe when and why they might be important.
Study NCT02653482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Study NCT02653482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapagliflozin matching placebo
Study NCT02084966 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure/Surgery: Transplantation: OCT of Kidney Transplant
Description: Device: Optical Coherence Tomography of Kidney Transplant
Study NCT03230916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMI/REL FDC
Description: IMI/REL is supplied as a single fixed dose combination (FDC) vial; which is administered at a maximum dose of 15 mg/kg IMI and 15 mg/kg CIL (up to 500 mg IMI and 500 mg CIL) and 7.5 mg/kg REL (up to 250 mg REL).
Study NCT02950246 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: perineural catheterization implementation
Description: Skin preparation (disinfection) with 10 ml of 2% alcoholic Chlorhexidine Perineural catheterization implementation Ultrasonography use
Study NCT02950246 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: perineural catheterization implementation
Description: Skin preparation (disinfection) with 10 ml of 2% alcoholic Chlorhexidine Perineural catheterization implementation Ultrasonography use
Study NCT02950246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% alcoholic chlorhexidine
Study NCT02950246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: povidon iodine
Study NCT01943201 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: new bedsheet
Description: sleeping 5 nights on the new bedsheet
Study NCT01943201 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: conventional bedsheet
Description: sleeping 5 nights on the conventional bedsheet
Study NCT03386370 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Indigo Mechanical Thrombectomy System
Description: Removal of acute clot (\< 14 days) from the artery causing lower limb ischemia, using the Indigo System by Penumbra
Study NCT01544868 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Use of Stable Isotope to Measure Energy Expenditure and Protein Turnover
Description: Two pre-dose urine specimens will be collected prior to an oral dose containing 0.22 g/kg total body water of 100% 18O water (or 1.2 g/kg per body weight of 10% 18O water) and 0.11 g/kg per body weight of 99.9% deuterium oxide. Then the patient will receive a single dose (4mg/kg, less than 2% of normal daily intake of 1.1g per person) of 15N glycine tracer. For this, patients will drink a dose of 15N glycine (4mg.kg 1dissolved in 20 ml of saline) mixed in 50 cc of apple juice or other liquid beverage, followed by a 50 cc wash of water. 24 hour urine collection will commence immediately. Twenty-four hour urines will be used for determining the 15N NH3 and 15N urea enrichment. Each urine container will contain 5 ml of 15N HCl for trapping the urinary ammonium. Urine will be collected each day for 3 days, for determination of the total urinary nitrogen, urea creatinine, and ammonia excretion.
Study NCT04195503 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Liver Transplantation
Description: Surgical removal of liver containing tumor(s) and transplantation of new healthy liver graft
Study NCT02515136 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Stimulus-response
Description: See summary
Study NCT03296176 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: blood sample for metabolome analyse
Study NCT01818245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541
Study NCT01257698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dorzolamide 2%-timolol 0.5% topical eyedrops
Description: Dorzolamide 2%-timolol 0.5%, 1 drop in operated eye twice daily until gas bubble completely resorbed. Patients randomized to this arm are instructed to use this drop in addition to standard post-operative eye drops.
Study NCT00328783 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Breathing Coordinator (ABC)
Description: The generated dose distributions from the free-breathing versus ABC plans will be compared to assess the volume of normal tissue, as well as target volume irradiated, utilizing dose-volume histograms.
Study NCT00328783 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Study NCT01783925 — intervention group
Intervention type: DRUG
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: Patients in daily life clinical practice treatment receiving EYLEA according to indication on the label.
Study NCT06526130 — intervention group
Intervention type: PROCEDURE
Intervention: General anaesthesia
Description: Intravenous or volatile general anesthesia was preformed with different type of airway management (endotracheal tube, laryngeal mask and bag mask ventilation)
Study NCT06526130 — intervention group
Intervention type: PROCEDURE
Intervention: Neuraxial anaesthesia
Description: spinal or epidural injections of local anesthetic with or without opioid
Study NCT02235428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Study NCT02235428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT02235428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Study NCT02235428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol
Study NCT00722111 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lingual press
Description: lingual press (high-intensity, oral, non-swallowing)
Study NCT00722111 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: effortful swallowing
Description: effortful swallowing (high-intensity swallowing)
Study NCT00722111 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: natural swallowing
Description: natural swallowing (high frequency, low intensity swallowing)
Study NCT00722111 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: non-oral sham (control) exercise
Description: non-oral sham (control) exercise
Study NCT04384341 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Bone densitometry (BMD)
Description: Recruitment of haemophilic patients during a routine visit at the haemophilia centre.~Information of the subjects that the study requires a BMD measure for all and a blood sampling for patients only.~After inclusion and exclusion criteria have been checked, the subject can sign the consent.~For all subjects, an appointment will be made for BMD measure.~For patients and controls: BMD will be measured by Dual Energy X-ray Absorptiometry (DXA) technology, on femoral and lumbar spine (L2-L4) sites.~Recruitment of healthy volunteers through registers (Clinical Investigation Centers) and advertisements.
Study NCT04384341 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Bone densitometry (BMD)
Description: Recruitment of haemophilic patients during a routine visit at the haemophilia centre.~Information of the subjects that the study requires a BMD measure for all and a blood sampling for patients only.~After inclusion and exclusion criteria have been checked, the subject can sign the consent.~For all subjects, an appointment will be made for BMD measure.~For patients and controls: BMD will be measured by Dual Energy X-ray Absorptiometry (DXA) technology, on femoral and lumbar spine (L2-L4) sites.~Recruitment of healthy volunteers through registers (Clinical Investigation Centers) and advertisements.
Study NCT02515136 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stimulus-response
Description: See summary
Study NCT04384341 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling for patients only
Description: For patients, fVIII/fIX activity and antigen, thrombin generation potential and plasmatic markers of bone remodelling will be measured centrally.
Study NCT03958981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Castor Oil
Description: The intervention group will be given 60 mL of castor oil in 140 mL of orange juice
Study NCT03958981 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the control group will be given a sunflower oil as a placebo with a similar texture to castor oil
Study NCT00636428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: oral midazolam, was prepared into a final solution (2.5 mg/mL) from injectable midazolam hydrochloride and a orange flavored syrup. For preparation, midazolam injection (5 mg/mL) was diluted 1:1 with the flavored syrup.
Study NCT02588131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tremelimumab plus MEDI4736
Description: tremelimumab1 mg/kg i.v over 60 minutes plus MEDI 4736 20 mg/kg i.v every four weeks for 4 doses, then MEDI4736 20 mg/kg IV every four weeks for additional 9 doses.
Study NCT00037973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ventilation feedback
Study NCT00037973 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ventilation feedback
Study NCT00037973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Study NCT00037973 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Study NCT02450409 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of TKA using the gap technique
Description: Implantation of total knee arthroplasty using a specific operative technique (GT) serving as control.
Study NCT02450409 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation of TKA using anatomical alignment
Description: Implantation of total knee arthroplasty using a specific operative technique (AA) being experimental.
Study NCT02834065 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiopulmonary bypass machine
Description: Routinely used cardiopulmonary bypass machine (standard of care) will be used to initiate circulatory arrest
Study NCT02746458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction
Description: Brief and intermittent blood flow restriction via a Delfi PTSII Tourniquet System will be used during physical therapy.
Study NCT02746458 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delfi PTSII Tourniquet System
Study NCT02331030 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supraclavicular
Description: Ultrasound-guided supraclavicular brachial plexus block
Study NCT02331030 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supraclavicular
Description: Ultrasound-guided supraclavicular brachial plexus block
Study NCT02331030 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pecs II block
Description: Ultrasound guided interfascial plane block between pectoralis minor and serratus anterior
Study NCT02331030 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham block (Grade 1)
Description: Sham block -- with skin preparation, ultrasound scanning of pecs II block area, but no actual needle injection
Study NCT02331030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% 20ml
Description: Local anaesthetic solution administered for supraclavicular block
Study NCT02331030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5% 20ml
Description: Local anaesthetic solution administered for supraclavicular block
Study NCT02331030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% 10ml
Description: Local anaesthetic solution administered for pecs II block
Study NCT01422720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine Acetate
Description: ESL tablets (800 mg) QD
Study NCT02832076 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subcutaneous negative suction drain for 10 days
Study NCT02832076 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No subcutaneous drain
Study NCT02087228 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genesys HydroTherm Ablator
Description: Heated water is circulated inside the uterus to destroy the lining of the uterus
Study NCT02087228 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency energy ablation device
Study NCT00108901 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program
Description: Vigorous intermittent physical activity in group format conducted in research gymnasium after school by research staff. Heart rate monitors documented each child's average heart rate on a daily basis. Small incentives were offered for achieving goal of >150 bpm average HR each day and attending at least 80% of sessions (4 days/week).
Study NCT04516694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive (gain)
Description: Participants will receive a daily financial incentive framed as a gain with money allocated each day of adherence to a self-care coal. Participants will receive an additional weekly incentive for meeting a clinical outcome goal.
Study NCT02075593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablets
Description: The DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablet is a purple, oval, biconvex tablets. The tablet contains 52.6 mg DTG sodium which is equivalent to 50 mg DTG free acid, 702 mg ABC sulphate which is equivalent to 600 mg ABC and 300 mg 3TC.
Study NCT02289391 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anesthesia induction
Description: -Intravenous injection midazolam 0.05 mg/Kg,fentanyl 4μg/Kg,etomidate 0.2 mg/Kg,cisatracurium 0.15 mg/Kg in proper order.
Study NCT02289391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthesia induction
Description: -Intravenous injection midazolam 0.05 mg/Kg,fentanyl 4μg/Kg,etomidate 0.2 mg/Kg,cisatracurium 0.15 mg/Kg in proper order.
Study NCT00850993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stannsoporfin
Description: Stannsoporfin administered as a single IM injection
Study NCT00850993 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (sterile saline solution) administered as a single IM injection
Study NCT00850993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PhotoTherapy (as needed)
Description: PT standard care administered as needed, based on bilirubin levels throughout the treatment period
Study NCT00850993 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PhotoTherapy (as needed)
Description: PT standard care administered as needed, based on bilirubin levels throughout the treatment period
Study NCT00730496 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: uterine cavity injection of day 2 embryo culture supernatant
Description: On the day 2, the embryos were translated from the old dish to a new dish with fresh media and cultured continuously. In study group, the embryo culture supernatant at the old dish were aspirated by using embryo transfer catheter (COOK-5000, Australia) and injected into the patient's uterine cavity. But in the control group, this intervention was not done. Conventional ET was performed on the third day of embryo culture for both groups.
Study NCT02222532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetronine
Description: Oral T3 was given 1 microgram/kgBW q6h since induction of anesthesia for 11 doses (for 60 hours)
Study NCT02222532 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was sacharum lactis, given q6h since induction of anesthesia for 11 doses (for 60 hours)
Study NCT05423015 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei strain Shirota
Description: Probiotic product were made in a Class II biosafety cabinet. Fifteen milliliters of the fermented milk food wich contains LcS were taken with a sterile syringe, and, at a subsequent time, 15 mL of sterile water were added to the probiotic product.
Study NCT05423015 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei strain Shirota plus inulin
Description: The Syn-inulin products were made in a Class II biosafety cabinet. Fifteen milliliters of the fermented milk food wich contains LcS were taken with a sterile syringe, and, at a subsequent time, 3 g of inulin (BENEO GmbH) were diluted in 15 mL of sterile water and added to Syn-inulin products.
Study NCT05423015 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei strain Shirota plus fructans from A. salmiana
Description: The Syn-A. salmiana products were made in a Class II biosafety cabinet. Fifteen milliliters of the fermented milk food wich contains LcS were taken with a sterile syringe, and, at a subsequent time, 3 g of fructans from A. salmiana were diluted in 15 mL of sterile water and added to Syn-A.salmiana products.
Study NCT01596634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01596634 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01596634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01596634 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: bovine lactoferrin
Description: Given PO
Study NCT04623671 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CAP-1002
Description: 100-mL (total volume) infusion of 150M CDCs in 5% Human Serum Albumin (HSA)
Study NCT04623671 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo solution
Study NCT00927316 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: E. coli 83972
Description: Active arm: Intravesical inoculation (by urethral catheterization) on three subsequent days with 30 ml E. coli 83972 (100 000 cfu/ml).~Placebo arm: Identical procedure but with saline, 30 ml.
Study NCT00927316 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: E. coli 83972
Description: Active arm: Intravesical inoculation (by urethral catheterization) on three subsequent days with 30 ml E. coli 83972 (100 000 cfu/ml).~Placebo arm: Identical procedure but with saline, 30 ml.
Study NCT04516694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive (loss)
Description: Participants will receive a daily financial incentive framed as a loss with money allocated up front and taken away each day of non-adherence to a self-care coal. An additional weekly incentive will be deducted for failure to meet a clinical outcome goal.
Study NCT04703530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hot footbath
Description: The experimental group was given a hot footbath with a temperature of 41℃±1℃ for 20 minutes at about 1-2 hours before sleep
Study NCT04128696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: feladilimab
Description: feladilimab is available as an intravenous infusion.
Study NCT04128696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is available as an intravenous infusion.